



# Medicine: nivolumab (brand name: Opdivo®) for advanced renal cell carcinoma

Bristol-Myers Squibb Pharmaceuticals Ltd

## What is nivolumab used for?

Nivolumab was considered for use to treat renal cell carcinoma (RCC), which is the most common type of kidney cancer in adults. It starts in the lining of tubes in the kidneys that are involved in filtering the blood and making urine. In advanced RCC the cancer has spread beyond the kidneys to other parts of the body. Nivolumab is used together with another medicine, called ipilimumab, to treat adults who have untreated advanced RCC and who are considered to be intermediate to poor risk.

## How does nivolumab work?

Nivolumab is an immunotherapy. This is a type of cancer treatment that stimulates the immune system (the body's natural defence system) to fight the cancer. Some cancer cells produce proteins that switch off certain immune cells (called T-cells). Nivolumab attaches to these T-cells, which stops the cancer switching them off, and helps the immune system fight the cancer.

### What has SMC said?

SMC has accepted nivolumab for the treatment of adults with advanced renal cell carcinoma as described above.



## Why has SMC said this?

SMC looks at how well new medicines work compared with current treatments available in Scotland and in relation to how much they will cost to buy and administer (for example, if the medicine has to be given at a clinic or side effects have to be monitored).

SMC carefully considers every new medicine to make sure it benefits patients and is considered to be an acceptable use of the limited resources in NHSScotland. When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not just those who may be treated with the medicine under consideration.

To do this SMC consider the following:

- Clinical trial and economic evidence from the company that makes the medicine.

- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
- Information from patient groups about the potential impact of the medicine on patients and carers.

After careful consideration, applying extra flexibility because nivolumab is a medicine for an end of life condition, and after the company applied a confidential discount to the cost of the medicine, SMC was able to accept it as a possible treatment within NHSScotland.

### What does SMC's decision mean for me?

If your healthcare professional thinks that nivolumab for use as described above is the right medicine for you, you should be able to have the treatment on the NHS in Scotland.

For further information see:

Medicines in Scotland: What's the right treatment for me?

[www.healthcareimprovementscotland.org/medicinesbooklet.aspx](http://www.healthcareimprovementscotland.org/medicinesbooklet.aspx)



### More information

The organisations below can provide more information and support for people with kidney cancer and their families. SMC is not responsible for the content of any information provided by external organisations.

#### Kidney Cancer Scotland



<https://www.kcuk.org.uk/scotland/>



0141 428 3494

#### Kidney Cancer Support Network



<http://www.kcsn.org.uk>



01209 890326

#### Kidney Research UK



<http://www.kidneyresearchuk.org>



0300 303 1100

You can find out more about nivolumab in the European public assessment report (EPAR) summary for the public by searching for the medicine name on the European Medicines Agency (EMA) website.



<http://www.ema.europa.eu>

**Date advice published:** 10 June 2019

**SMC No:** (SMC2153)